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Background: Whereas thermal ablation of incompetent saphenous veins is highly effective, all heat-based ablation tech-
niques require the use of perivenous subfascial tumescent anesthesia, involving multiple needle punctures along the course
of the target vein. Preliminary evidence suggests that cyanoacrylate embolization (CAE) may be effective in the treatment
of incompetent great saphenous veins (GSVs). We report herein early results of a randomized trial of CAE vs radio-
frequency ablation (RFA) for the treatment of symptomatic incompetent GSVs.
Methods: Two hundred twenty-two subjects with symptomatic GSV incompetence were randomly assigned to receive
either CAE (n [ 108) with the VenaSeal Sapheon Closure System (Sapheon, Inc, Morrisville, NC) or RFA (n [ 114)
with the ClosureFast system (Covidien, Mansﬁeld, Mass). After discharge, subjects returned to the clinic on day 3 and
again at months 1 and 3. The study’s primary end point was closure of the target vein at month 3 as assessed by duplex
ultrasound and adjudicated by an independent vascular ultrasound core laboratory. Statistical testing focused on showing
noninferiority with a 10% delta conditionally followed by superiority testing. No adjunctive procedures were allowed until
after the month 3 visit, and missing month 3 data were imputed by various methods. Secondary end points included
patient-reported pain during vein treatment and extent of ecchymosis at day 3. Additional assessments included general
and disease-speciﬁc quality of life surveys and adverse event rates.
Results: All subjects received the assigned intervention. By use of the predictive method for imputing missing data,
3-month closure rates were 99% for CAE and 96% for RFA. All primary end point analyses, which used various methods
to account for the missing data rate (14%), showed evidence to support the study’s noninferiority hypothesis (all
P < .01); some of these analyses supported a trend toward superiority (P [ .07 in the predictive model). Pain expe-
rienced during the procedure was mild and similar between treatment groups (2.2 and 2.4 for CAE and RFA,
respectively, on a 10-point scale; P [ .11). At day 3, less ecchymosis in the treated region was present after CAE
compared with RFA (P < .01). Other adverse events occurred at a similar rate between groups and were generally mild
and well tolerated.
Conclusions: CAE was proven to be noninferior to RFA for the treatment of incompetent GSVs at month 3 after the
procedure. Both treatment methods showed good safety proﬁles. CAE does not require tumescent anesthesia and is
associated with less postprocedure ecchymosis. (J Vasc Surg 2015;61:985-94.)the Morrison Vein Institute, Scottsdalea; the Lake Washington
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://dx.doi.org/10.1016/j.jvs.2014.11.071Chronic venous disorders (CVDs) are progressive med-
ical conditions that afﬂict approximately 30 million adults in
the United States or approximately 35% of screened adults
in the United States 1 and the United Kingdom.2 In the
most commonmanifestation of CVD, the valves in the great
saphenous vein (GSV) and other superﬁcial veins transport-
ing blood from the legs toward the heart are dysfunctional,
leading to venous dilation and stasis, causing symptoms and
physical ﬁndings such as fatigue, swelling, pain, chronic skin
changes, spontaneous hemorrhage, and leg ulcers. As CVD
progresses, symptoms can be burdensome and profoundly
affect quality of life. In the United States, time away from
work due toCVD exceeds work time lost from peripheral ar-
tery disease.3 Nonetheless, only a small fraction of those
with CVD seek treatment.4
Treatment of CVD and saphenous insufﬁciency has
undergone a substantial shift in the past decade. Previ-
ously, surgical treatment (ligation and stripping) was the
primary treatment choice, in most cases requiring a
general or regional anesthetic in an operating room. Com-
plications from surgical treatments include hematoma,985
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rence rate.5-7
Endovenous thermal ablation (EVTA) by radiofre-
quency ablation (RFA) or laser ablation has been shown
to be a safe and effective treatment of CVD with high
long-term target vein closure rates.8 Both techniques
have gained broad acceptance in many countries and by
multiple specialties. One disadvantage of these techniques
is the requirement for use of tumescent anesthesia (TA),
which provides necessary local anesthesia, protects sur-
rounding structures from potential thermal injury gener-
ated through the RF catheter and laser ﬁbers, and
reduces the caliber of the target vein to evacuate as much
blood as possible to enhance vein wall thermal injury. TA
not only requires additional time during a procedure but
may also be associated with adverse events, such as pain,
hematoma, and ecchymosis.7-9 New treatments that
circumvent the need for TA are desirable, provided treat-
ment efﬁcacy remains high.
Cyanoacrylate embolization (CAE) for varicose veins
(VenaSeal; Sapheon, Inc, Morrisville, NC) has recently
been approved for treatment of the incompetent GSV in
the European Union, Hong Kong, and Canada. Cyanoac-
rylate adhesive (CA) has a long history of medical use, most
notably in the embolic treatment of intracranial arteriove-
nous malformations.10 Recently, a modiﬁed CA has been
developed with the following desirable properties: (1) rapid
polymerization on contact with blood and tissue, (2) ﬂex-
ibility sufﬁcient to tolerate dynamic movement in the legs
without generation of symptoms or being perceptible by
the patient, and (3) high viscosity to eliminate the risk of
embolization to the deep veins or pulmonary circulation.
Two prospective clinical trials provided early evidence
of CAE’s safety and effectiveness. In the ﬁrst trial, 38 sub-
jects at a single center with symptomatic GSV reﬂux treated
with CAE had a 92% 12-month target vein closure rate.11
In a second study (the European Sapheon Closure System
Observational ProspectivE [eSCOPE]), 70 subjects treated
at seven sites in Europe had a 93% 12-month closure
rate.12 In neither of these studies did subjects receive peri-
venous TA or require postprocedure compression stock-
ings. Subjects in both studies demonstrated clinically and
statistically signiﬁcant improvements in symptoms and
health-related quality of life.
We report initial results of VeClose in a prospective,
multicenter randomized clinical trial comparing CAE
with RFA for the treatment of the incompetent GSV.
Because RFA with ClosureFast has been shown to cause
less ecchymosis and pain in the postoperative follow-up
period compared with laser ablation,13 we chose RFA as
the comparator for this pivotal trial of the effectiveness
and safety of CAE. The goal of the study was to show sta-
tistical noninferiority of CAE efﬁcacy compared with RFA.
METHODS
Study design. VeClose is a multicenter, prospective
randomized controlled trial conducted under investiga-
tional device exemption from the U.S. Food and DrugAdministration at 10 participating sites in the United
States. The goal of the study was to show statistical nonin-
feriority of CAE efﬁcacy compared with RFA. Subjects
were enrolled between March and September 2013. All
sites obtained central Institutional Review Board approval
before enrollment. The study underwent rigorous remote
and on-site monitoring as well as 100% source veriﬁcation.
Study subjects. The study enrolled adults aged 21 to
70 years with symptomatic moderate to severe varicosities
(Clinical, Etiology, Anatomy, and Pathophysiology
[CEAP] clinical classiﬁcation of symptomatic C2-C4b) and
incompetence of the GSV, with reﬂux time of at least
0.5 second assessed in the standing position. Subjects were
excluded if they had hemodynamically signiﬁcant reﬂux of
the small saphenous vein or anterior accessory GSV, prior
treatment of the target GSV, symptomatic peripheral arterial
disease, a history of deep venous thrombosis or pulmonary
embolism, or aneurysm of the target GSV >12 mm in
diameter (additional eligibility criteria are shown in Table I).
After eligibility was conﬁrmed and informed consent
was obtained, subjects underwent baseline examination,
including a brief, focused physical examination, completion
of CEAP and Venous Clinical Severity Score (VCSS) as-
sessments,14 and duplex ultrasound of both legs. In addi-
tion, subjects completed the EQ-5D quality of life
survey15 and the Aberdeen Varicose Vein Questionnaire
(AVVQ).16 Subjects were then randomized (1:1) to CAE
performed with VenaSeal Sapheon Closure System
(VSCS; Sapheon, Inc, Morrisville, NC) or RFA performed
with ClosureFast (Covidien, Mansﬁeld, Mass). Randomi-
zation was stratiﬁed by study site and used random block
sizes of 4 or 6; assignments were obtained with an interac-
tive voice response system linked to a web-based database.
The ﬁrst two subjects at each site were not randomized but
rather treated with CAE (ie, roll-in cases) to ensure famil-
iarity with the CAE procedure. All operators were experi-
enced with EVTA procedures and were currently using
RFA. Because study outcomes in roll-in subjects (n ¼
20) did not differ from the randomized cohort (n ¼
222), this report excludes discussion of roll-in cases.
Devices and procedures. VSCS consists of a delivery
system and proprietary CA. Endovenous embolization
of the GSV with VSCS was performed as previously
described.11 Brieﬂy, with high-resolution ultrasound guid-
ance, a 5F introducer sheath/catheter was advanced to the
saphenofemoral junction (SFJ) and positioned 5.0 cm caudal
to the SFJ. With proximal GSV compression by the ultra-
sound probe, two injections of approximately 0.10 mL
CA were given 1 cm apart at this location, followed by a
3-minute period of local compression, and then repeated
injections and 30-second ultrasound probe and hand
compression sequences until the entire length of the target
vein segment was treated. The sheath/catheter was removed
and compression applied to the catheter entry site until he-
mostasis was achieved. A single small bandage was applied,
and venous occlusion was conﬁrmed by duplex ultrasound.
RFA of the target vein was performed with Closure-
Fast according to the manufacturer’s instructions for use.
Table I. Study eligibility criteria
Inclusion criteria
1. Age $21 years and #70 years at the time of screening
2. Reﬂux in the GSV >0.5 second
3. One or more of the following symptoms related to the target vein: aching, throbbing, heaviness, fatigue, pruritus, night cramps,
restlessness, generalized pain or discomfort, swelling
4. GSV diameter while standing of 3-12 mm throughout the target vein as measured by duplex ultrasound
5. CEAP classiﬁcation of C2 (if symptomatic)-C4b
6. Ability to walk unassisted
7. Ability to attend follow-up visits
8. Ability to understand the requirements of the study and to provide informed consent
Exclusion criteria
1. Life expectancy <1 year
2. Active treatment for malignant disease other than nonmelanoma skin cancer
3. Symptomatic peripheral arterial disease with ABI <0.89
4. Daily use of narcotic or nonsteroidal anti-inﬂammatory pain medications to control pain associated with GSV reﬂux
5. Current, regular use of systemic anticoagulation (eg, warfarin, heparin)
6. Previous or suspected deep venous thrombosis or pulmonary embolus
7. Previous superﬁcial thrombophlebitis in the target GSV
8. Previous treatment of venous disease in target limb, other than spider vein treatment
9. Known hypercoagulable disorder
10. Conditions that prevent vein treatment with either RFA or VSCS
11. Immobilization or inability to ambulate
12. Pregnant before enrollment
13. Tortuous GSV, which, in the opinion of the investigator, will limit catheter placement or require more than one primary access site
14. Aneurysm of the target vein with local vein diameter >12 mm
15. Signiﬁcant, incompetent, ipsilateral small saphenous veins, intersaphenous veins, or anterior accessory GSVs
16. Known sensitivity to cyanoacrylate adhesives
17. Current participation in another clinical study involving an investigational agent or treatment or within the 30 days before enrollment
18. Patients who require bilateral treatment during the next 3 months
19. Patients who require additional ipsilateral treatments on the same leg within 3 months following treatment
ABI, Ankle-brachial index; CEAP, clinical, etiology, anatomy, and pathophysiology classiﬁcation; GSV, great saphenous vein; RFA, radiofrequency ablation;
VSCS, VenaSeal Sapheon Closure System.
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ment surrounding the vein, and the dosage was recorded.
Use of reprocessed catheters was not allowed. Double cy-
cles of RF were employed at the ﬁrst treatment zone near
the SFJ in all subjects.
All procedures took place in an outpatient setting at the
investigator’s clinic with use of standard sterile technique.
Immediately after venous access, subjects rated their pain
on venous access on a numeric rating scale of 0 to 10 (0,
no pain; 10, worst imaginable pain). When the procedure
was completed, subjects used the same scale to rate intrao-
perative pain experienced during the procedure itself,
including during TA but excluding pain felt during venous
access. Subjects were discharged from the clinic on comple-
tion of the procedure. Consistent with the ClosureFast in-
structions for use, postprocedure compression stockings
were used in both groups for 3 days continuously and an
additional 4 days during waking hours. Subjects were
instructed to avoid strenuous activities for 1 to 2 days.
Postoperative study visits. Subjects returned to the
clinic at day 3 for a brief clinical assessment, including
the subject’s reporting of pain medications taken within
24 hours, the subject’s rating of pain experienced in the in-
dex leg, and the investigator’s assessment of the presence of
ecchymosis, rated on a previously used 0- to 5-point
graded scale (0, none; 1, involving <25% of the treat-
ment area; 2, 25%-50%; 3, 50%-75%; 4, 75%-100%; 5,extension above or below the treatment segment).13 Sub-
jects also returned at month 1 and month 3 for clinical
assessment (including CEAP score [month 3 only] and
VCSS), quality of life evaluation (AVVQ and EQ-5D), and
duplex ultrasound examination of the treated limb. The
allowed 3-month window was 64 weeks. No subject un-
derwent ipsilateral adjunctive varicose vein treatments until
the 3-month visit was complete to evaluate index device/
procedure efﬁcacy without the potential for confounding
by additional therapies. Trial follow-up continues to
36 months after index treatment.
Adverse events were monitored at each study visit by
querying subjects using a list of expected adverse events
with RFA and CAE procedures. Investigators rated event
severity as well as the relationship of the adverse events
to the device and the procedure. Safety was reviewed by
an independent data safety and monitoring board.
End points and statistical methods. The study’s pri-
mary end point was complete closure of the target GSV,
deﬁned as Doppler ultrasound examination (including co-
lor ﬂow, compression, and pulsed Doppler) showing
closure along the entire treated target vein segment with
no discrete segments of patency exceeding 5 cm at the
month 3 visit. Closure was conﬁrmed by an independent
vascular ultrasound core laboratory (VasCore, Boston,
Mass). Incomplete closure seen with any of these methods
counted against the primary end point. The primary end
Fig 1. Study disposition. CAE, Cyanoacrylate embolization; RFA, radiofrequency ablation. *All out-of-window scans
showed complete occlusion of the target vein.
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following prespeciﬁed methods to impute missing data: last
observation carry forward, pessimistic and optimistic
models, and Bayesian predictive models. Predictive models,
used for missing RFA observations only, took into account
the following in-study factors predictive of incomplete
occlusion: male gender, decreased body mass index, and
number of tributaries >3 mm in diameter. The study was
interpreted as a primary end point success if the proportion
of subjects with complete closure with CAE was statistically
noninferior to that with RFA, with a 10% noninferiority
margin. Proportions were compared by c2 tests for two
independent binomial event rates, and conﬁdence limits
were calculated by the method of Miettinen and Nurmi-
nen.17 Noninferiority was concluded when the P value
was < .05 and the lower conﬁdence interval for the dif-
ference in success rates exceeded 10%. If noninferiority
was demonstrated, superiority was then tested by similar
methods.The study’s two secondary end points were subject-
rated pain experienced during the procedure (ie, pain expe-
rienced after vein access but before all treatment/access
catheters were removed) and investigator-rated ecchymosis
at day 3. Treatment differences for the former were
compared by a two-tailed t-test, the latter by a Wilcoxon
test. Changes from baseline in VCSS, AVVQ, and EQ-
5D were compared between groups by repeated-measures
analysis of variance and a Wilcoxon test for CEAP category
at month 3. The rates of adverse events were compared by
Fisher exact test. All analyses were performed with R, an
open-source statistical package.18
RESULTS
Subject characteristics and disposition. Of 488 pa-
tients screened at 10 sites between March and September
2013, 242 met enrollment criteria and were enrolled
(Fig 1). The ﬁrst two subjects at each site (20 total) were
treated with CAE in the roll-in phase; 222 subjects were
Table II. Demographic and baseline characteristics of VeClose study subjects
Characteristic VSCS (n ¼ 108) RFA (n ¼ 114) P value
Femalea 83 (77) 93 (82) .48
Hispanica 4 (4) 8 (7) .43
Nonwhitea 6 (6) 8 (7) .32
Target lega
Right 47 (44) 56 (49) .48
Left 51 (57) 58 (51)
Age, mean (range)b 49.0 (26.6-70.6) 50.5 (25.6-70.1) .34
Body mass index, mean (range)b 27.0 (17.4-44.5) 27.0 (17.0-46.7) .95
Primary symptoma
Pain 33 (31) 24 (21) .65
Aching 32 (30) 39 (34)
Swelling 17 (16) 18 (16)
Heaviness 14 (13) 16 (14)
Burning 5 (5) 3 (3)
Itching 2 (2) 5 (4)
Other 4 (4) 7 (6)
Smokinga
Current 16 (15) 5 (4) .02
Former 25 (23) 35 (31)
Never 66 (61) 74 (65)
GSV diameter, mean (range), mmb
Mid GSV 4.9 (0-9) 5.1 (2.4-11) .28
Proximal GSV 6.3 (3-12) 6.6 (2.8-12) .15
CEAP categorya
C2 (varicose veins) 61 (57) 64 (56) .96
C3 (edema) 32 (30) 36 (32)
C4a (pigmentation/eczema) 13 (12) 12 (11)
C4b (lipodermatosclerosis and atrophie blanche) 2 (2) 2 (2)
VCSS, mean (SD)b 5.5 (2.6) 5.6 (2.6) .99
AVVQ, mean (SD)b 18.9 (9.0) 19.4 (9.9) .72
EQ-5D TTO, mean (SD)b 0.935 (0.113) 0.918 (0.116) .29
AVVQ, Aberdeen Varicose Vein Questionnaire; CEAP, clinical, etiology, anatomy, and pathophysiology classiﬁcation; GSV, great saphenous vein; RFA,
radiofrequency ablation; SD, standard deviation; TTO, time trade-off; VCSS, Venous Clinical Severity Score; VSCS, VenaSeal Sapheon Closure System.
Data are presented as number (%) unless otherwise indicated.
aBinary or ordinal outcomes tested by c2 tests.
bContinuous outcomes tested by unpaired t-tests.
Table III. Procedure characteristics
Characteristic VSCS (n ¼ 108) RFA (n ¼ 114) P valuea
Treatment zone maximum diameter, mm 5.9 (2-12) 6.2 (1.5-11) .19
GSV treatment length, cm 32.8 (8-61) 35.1 (6.5-84.5) .17
Tumescent anesthesia amount, mL d 272 (50-550) d
Stump length, cm 22.5 (0-83) 18.9 (0-330) .38
CA delivered, mL 1.2 (0.4-2.3) d d
Procedure duration, minutes 24 (11-40) 19 (5-46) <.01
Volume lidocaine, mL 1.6 (0.2-6) 2.7 (0.2-10) .1
CA, Cyanoacrylate adhesive; GSV, great saphenous vein; RFA, radiofrequency ablation; VSCS, VenaSeal Sapheon Closure System.
Data are presented as mean (range).
aP values derived from unpaired t-test or Wilcoxon test.
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Volume 61, Number 4 Morrison et al 989randomly assigned to either CAE or RFA. All subjects
returned for the day 3 visit, and subsequently a small and
similar number of subjects in each group were lost to
follow-up or voluntarily withdrew. The majority of subjects
were women (79%) and white (94%) (Table II). Most
(87%) subjects had CEAP clinical class 2 and 3 venous
disease. There was a slight predominance of current and
former smokers in the CAE groups (P ¼ .02). Thepredominant symptoms were leg pain and aching. Risk
factors for varicose veins were common and similar be-
tween groups. VCSS and AVVQ scores were consistent
with mild to moderate venous reﬂux disease. Baseline
characteristics were similar between treatment groups.
Procedure characteristics. All subjects received the
assigned intervention. The average maximum diameter of
the GSV in the treatment zone was 6 mm (Table III).
Fig 2. Ultrasound images of incompetent great saphenous vein
(GSV) (A) before treatment and (B) after treatment with cyano-
acrylate embolization (CAE) and (C) after treatment with radio-
frequency ablation (RFA).
Fig 3. Complete closure of cyanoacrylate embolization (CAE)-
treated incompetent great saphenous vein (GSV) with stump
length calipers.
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tributaries >3 mm in diameter. Mean procedure time was
5 minutes longer for CAE vs RFA (24 vs 19 minutes; P <
.01). At the end of the procedure, one subject each in the
CAE and RFA groups had residual ﬂow along the treated
segment. Five (4%) technical deviations occurred during
RFA treatment, requiring use of an additional separate
hydrophilic guidewire (Cook HiWire, Bloomington, Ind)
in four cases to assist in proximal positioning of the RFA
catheter. No technical deviations occurred during CAE
treatment. Fig 2 shows an ultrasound image of the GSV
before (A) and after (B and C) the CAE and RFA
procedure.Venous closure. On day 3, 100% of GSVs were closed
in both groups (Fig 3). At month 1, patency of the treated
vein segment on duplex ultrasound was identiﬁed in 15
GSVs treated with RFA and 0 GSVs treated with CAE,
with closure rates of 86% and 100%, respectively (P < .01
for both noninferiority and superiority). Of the 222 ran-
domized subjects, a 3-month visit was done in 212 (96%),
of which 7 (3%) were out of window. Month 3 Doppler
ultrasound images, used for the core laboratory’s assess-
ments, were available in 194 of 222 subjects. Ultrasound
images were missing or uninterpretable in 15 CAE and 16
RFA cases (total missing rate of 14%; Fisher exact, P ¼
1.0). Missing images were due to early withdrawal (n ¼ 8
and 6 in the CAE and RFA groups, respectively), unin-
terpretable images (3 RFA cases), and images beyond the
allowed 3-month study window (n ¼ 7 and 7 in the CAE
and RFA groups). All out-of-window images showed
complete occlusion. For available images, there was 100%
agreement between site investigator and core laboratory
readings of target vein closure.
Among available images, the GSV was patent in ﬁve
RFA-treated subjects and one CAE-treated subject. Taking
into account the 31 missing images using several prespeci-
ﬁed imputation methods (Table IV), statistical noninferior-
ity was demonstrated with P values < .01 in all models.
In three of the ﬁve missing data imputation methods,
there was a trend toward statistical superiority for CAE
(P ¼ .06, .06, and .07). With use of the predictive model
for missing data interpretation, closure rates were 99%
and 96% in the CAE and RFA groups, respectively.
Pain and ecchymosis. Mean pain ratings during
venous access were similar between the two groups (1.6
for CAE vs 2.0 for RFA; P ¼ .13); mean intraprocedural
pain ratings were also low and similar in both groups
(2.2 vs 2.4; P ¼ .11). There was no difference between
treatment groups in pain experienced in the 24 hours
Table IV. Primary end point analyses under various models for imputing missing data
Model Description
Closure rate
Rate difference
(95% CI) PNI PSup
VSCS
(n ¼ 108)
RFA
(n ¼ 114)
Last observation
carry forward
Most recent ultrasound observation used
to impute missing value
107 (99%) 109 (96%) 3.5% (0.7% to 8%) <.01 .06
Optimistic Assume missing values are successes 107 (99%) 109 (96%) 3.5% (0.7% to 8%) <.01 .06
Pessimistic Assume missing values are failures 92 (85%) 93 (82%) 3.6 (6.2 to 13) <.01 .24
Alternative
pessimistic
Assume missing values are failures but late
month 3 evaluations are successes
99 (92%) 100 (88%) 3.9 (4.0 to 12) <.01 .17
Predictive Estimate distribution of successes taking
into account gender, body mass index,
and number of tributaries $3 mm
99%a 96% 4% <.01 .07
CI, Conﬁdence interval; PNI, P value for noninferiority; PSup, P value for superiority; RFA, radiofrequency ablation; VSCS, VenaSeal Sapheon Closure System.
aNumber not reported as predictive values are distributions, not ﬁxed values.
Fig 4. Ecchymosis assessed by investigators with a 5-point scale
on day 3 by treatment group. Subjects treated with cyanoacrylate
embolization (CAE) had less ecchymosis at day 3 compared with
radiofrequency ablation (RFA) (P < .01, Wilcoxon test).
Table V. Follow-up clinical assessments
VenaSeal (n ¼ 108) RFA (n ¼ 114) P valuea
VCSS
Baseline 5.5 (2.6), 108 5.6 (2.6), 114 .60
Day 3 4.9 (1.3), 108 5.0 (1.9), 114
Month 1 2.3 (1.7), 105 2.6 (2.0), 110
Month 3 1.9 (1.6), 104 2.0 (2.0), 108
AVVQ
Baseline 18.9 (9.0), 107 19.4 (9.9), 111 .53
Month 1 11.9 (7.1), 102 12.6 (8.3), 109
Month 3 11.6 (7.5), 104 10.7 (8.6), 108
EQ-5D TTO
Baseline 0.935 (0.113), 108 0.918 (0.116), 114 .34
Month 1 0.965 (0.113), 105 0.961 (0.106), 110
Month 3 0.965 (0.095), 104 0.965 (0.083), 108
AVVQ, Aberdeen Varicose Vein Questionnaire; RFA, radiofrequency
ablation; TTO, time trade-off; VCSS, Venous Clinical Severity Score.
Values are given as mean (standard deviation), number.
aP values are derived from repeated-measures analysis of variance.
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mosis severity at day 3 was lower in the CAE group (P <
.01; Fig 4), and ecchymosis at day 3 was absent in signif-
icantly more subjects after CAE than after RFA (68% of
CAE subjects vs 48% of RFA subjects; P < .01).
Clinical measures. Additional measures of clinical
severity of CVD showed marked, sustained, and equal re-
ductions in both groups over time (Table V). By month
3, VCSS had improved approximately 3.5 points from
baseline (P < .01), with no differences between treat-
ment groups. Similarly, by month 3, AVVQ score
improved by approximately 8 points (P < .01), and EQ-
5D time trade-off utility index had improved by
approximately 0.03 unit (P ¼ .01), with no differencesbetween treatment groups. At baseline, no subject was
CEAP 0/1; by month 3, 26% and 33% of subjects in the
CAE and RFA groups were CEAP 0/1. CEAP improved
by approximately 0.5 point per group (P < .01), with no
difference between groups.
Safety. No subject withdrew because of an adverse
event and no subject developed deep venous thrombosis
or pulmonary embolism. Four mild adverse events occurred
during the RFA procedure and one occurred after the CAE
procedure (RFA: lightheadedness [1], nausea [1], and vaso-
vagal symptoms [2]; CAE: lightheadedness after the proce-
dure). As of the month 3 visit, 78 adverse events had
occurred in 63 subjects (34 CAE subjects and 29 RFA sub-
jects; Table VI; P ¼ .37 for difference in number of adverse
events per subject between treatment groups). The type and
rate of expected predeﬁned adverse events were similar be-
tween treatments, except that post-treatment phlebitis (in
the treated segment or nontreated tributary) was somewhat
more common after CAE (20 vs 15 events; P ¼ .36). Most
cases of phlebitis in both groups were mild, transient, and
Table VI. Adverse events
VenaSeal, No. (%) RFA, No. (%) P valuea
No. of adverse events per subject
0 74 (69) 85 (75) .37
1 28 (26) 22 (19)
2 6 (6) 6 (5)
3 0 (0.0) 0 (0.0)
4 0 (0.0) 1 (1)
Event severity
Mild 26 (24) 30 (26) .35c
Moderate 12 (11) 7 (6)
Severe 2 (2) 1 (1)
Procedure-related adverse eventsb 27 (25) 31 (27) .76
Device-related adverse eventsb 13 (12) 7 (6) .16
Reported adverse events
Phlebitis, any zone 22 (20) 16 (14) .36
Phlebitis in treatment zone 11 (10) 10 (9) .82
Phlebitis not in treatment zone 8 (7) 4 (4) .24
Phlebitis in both treatment zone and nontreatment zone 1 (1) 1 (1) 1.0
Paresthesia in treatment zone 3 (3) 3 (3) 1.0
Stocking irritation 2 (2) 3 (3) 1.0
Access site infection 1 (1) 1 (1) 1.0
Superﬁcial thrombophlebitis 4 (4) 3. (3) .72
Access site burn 0 (0) 1 (1) 1.0
Paresthesia not in treatment zone 0 (0) 1 (1) 1.0
Other adverse eventsd 10 (9) 11 (10) 1.0
RFA, Radiofrequency ablation.
Percentages represent number of events divided by number treated.
aP values derived from c2 test, Wilcoxon test, or Fisher exact test.
bJudged by investigator to be probably or deﬁnitely related.
cCochrane-Armitage trend test.
dAdverse events not related to varicose veins or the treatment area.
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inﬂammatory medication (ibuprofen). Three adverse events
were rated severe (one case each of breast cancer, kidney
stones, and symptomatic orthostatic hypotension), none of
which was deemed related to either the index device or
procedure. No device- or procedure-related serious adverse
events occurred in either group, and no postprocedural
thrombus extensions into the common femoral vein were
identiﬁed by duplex ultrasound in any patient.
In both treatment groups, the number of adverse
events that investigators attributed to the study device
was small (Table VI). Events rated as probably or deﬁnitely
related to CAE devices included moderate access site infec-
tion (1), mild paresthesia in the treatment zone (1), mod-
erate paresthesia in the treatment zone (1), mild phlebitis
in the treatment zone (6), moderate phlebitis not in the
treatment zone (1), and mild superﬁcial vein thrombophle-
bitis (3). Events rated as probably or deﬁnitely related to
RFA study devices included mild access site burn (1),
mild paresthesia in the treatment zone (2), mild phlebitis
in the treatment zone (2), moderate phlebitis in the treat-
ment zone (1), and mild phlebitis not in the treatment
zone (1).
DISCUSSION
Results from this study conﬁrm that CAE is safe and
highly effective for the treatment of CVD. The study
showed that occlusion of the target vein at 3 months byCAE was at least as effective as RFA. Short-term (3-month)
probability of complete closure of the target GSV with
CAE in this study was high (99%) and similar to that
observed in a prior single-arm CAE study (95% in a small
feasibility study19) and in a prospective CAE multicenter
European study (96%).12 High long-term GSV closure
rates with RFA (93% at 3 years) have been reported,20
although a meta-analysis reported somewhat lower long-
term success rates (84% at 3 years8). The reports in this
meta-analysis included the use of an earlier generation RF
system (VNUS Closure; VNUS Medical Technologies,
San Jose, Calif), which may be the reason for lower success
rates than are seen with newer RF equipment. In addition,
methods to assess complete occlusion varied slightly across
studies. Closure rate associated with RFA may have been
lower in this study because of the critical ultrasound evalu-
ation performed at each study center. Long-term follow-up
from the current study may provide the best estimate of
differences in venous closure rates between CAE and RFA.
In previous reports of CAE treatment of GSV, incom-
plete occlusion and recanalization appeared to be caused
by continued ﬂow of blood from GSV tributaries into the
treated GSV, resulting in areas of failed closure. In the
present study, high closure rates (especially in the CAE
treatment group) were seen despite use of a stricter deﬁ-
nition of vein closure (only 5 cm of patency allowed vs
10 cm used in some other studies13) and in the absence
of adjunctive treatments at the time of index treatment.
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withheld at the time of the index procedure when highly
effective GSV closure methods are used, such as RFA or
CAE, and delivered later, if required, as has been previ-
ously suggested.21,22
Both CAE and RFA were associated with low pain
scores. Moreover, presumably because it does not require
TA, CAE treatment resulted in less ecchymosis over the
treated segment at day 3 compared with subjects treated
with RFA. In addition, in controlled studies comparing
RFA with ClosureFast to laser ablation, pain and ecchy-
mosis measurements were also somewhat dissimilar to
those in our studies.13,23 In these studies, pain was not
rated immediately after the procedure, as was done in our
study. These differences make comparisons of some aspects
of our study with previous studies difﬁcult.
The severity and impact of venous disease on quality of
life were measured with several end points in this study.
Both CAE-treated and RFA-treated subjects improved
signiﬁcantly over time. VCSS scores of 1.5 points at
3 months, with signiﬁcant improvements from baseline, are
similar to those seen in previousCAEclinical trials.12,19 Like-
wise, subjects’ improvements in AVVQ and EQ-5D were
similar to those previously reported with CAE treatment.19
Although CEAP class improved signiﬁcantly in both treat-
ment groups, the importance of this ﬁnding is unclear.
Adverse events were similar between groups. No severe
procedure- or device-related adverse events occurred in either
group. Device-related adverse events with CAE were mostly
cases of phlebitis of the treated GSV and, although not statis-
tically signiﬁcant, occurred somewhat more commonly than
in RFA-treated subjects (20 vs 15 cases; P ¼ .36). The differ-
ence might reﬂect the mechanism of action of the adhesive.
Most cases of phlebitis in both groups were mild, transient,
and successfully treated with over-the-counter nonsteroidal
anti-inﬂammatory medication (ibuprofen). Slight technical
deviations (use of additional guidewire), although minor,
were experienced during only the RFA procedures.
The current study has several novel features compared
with other clinical trials of treatments for CVD. A random-
ized active control group (RFA) allowed the observed
closure rate for CAE to be compared in the same operator/
investigator group. This study was tightly controlled, moni-
tored, and 100% source veriﬁed, yielding high-quality data.
The investigators’ ultrasound results were conﬁrmed by an
independent vascular ultrasound core laboratory. The
study’s primary end point (occlusion of the target GSV)
was objective and easily judged, with full agreement be-
tween investigator and core laboratory readings. Moreover,
the study’s primary ultrasonographic end point was more
strictly deﬁned than that used in some other studies of
EVTA.24 Given the high target vein occlusion rate in both
groups, the observed improvements in CVD-associated
symptoms (as assessed by VCSS and AVVQ) and general
quality of life (as assessed with EQ-5D) were expected,
with no signiﬁcant difference between treatment groups
found. Finally, the multicenter, multioperator performance
of the study increases study validity by reporting thecombined experience of multiple physician participants,
removing the bias of a single-center/operator study. Study
follow-up will continue to 3 years, allowing documentation
of longer term index vein success rates as well as the likeli-
hood of recanalization or CVD progression.
Although this study has some limitations, the results are
signiﬁcant even though data were missing in a small number
of subjects. However, all methods used to impute missing
data (including pessimistic models) provided strong evi-
dence of noninferiority. The assessment of vein closure
could not be blinded to treatment because the ultrasono-
graphic appearance of the implanted cyanoacrylate is unique
and different from that observed after RFA treatment. There
was complete agreement, however, between site investiga-
tors and the core laboratory for all vein closure assessments.
To reduce bias between groups, post-treatment stockings
were worn by both CAE and RFA subjects because the
RFA instructions for use require compression. Saphenous
occlusion rates were high in prior studies of CAE without
use of compression. Finally, adjunctive treatments were
withheld until after the month 3 visit to prevent confound-
ing variables in the primary occlusion analysis.
The advantages of CAE for the treatment of incompe-
tent truncal veins are, ﬁrst, because CAE does not require
the use of TA, the patient avoids its associated burden; and
second, CAE may also allow elimination of postprocedure
compression stockings, for which compliance is known to
be poor.25,26CONCLUSIONS
In the current study, CAE was shown to be noninferior
to RFA for the occlusion of symptomatic incompetent
GSVs at 3 months. CAE does not require TA, which
resulted in reduced side effects such as ecchymosis
compared with RFA. The rate of postoperative phlebitis
was slightly higher for CAE but not statistically signiﬁcant
compared with RFA.
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